S017 Great Care for Common Conditions: Combining Evidence and Cost Effectiveness
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will examine the data and provide an evidenced based discussion about best cost effective practices to care for patients with photoaging, acne, psoriasis, HS, as well as hair and nail disease.
This session will provide an opportunity to review and apply some time-honored strategies, as well as a few new ones, to the factors that make our lives feel out of control. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org
LEARNING OBJECTIVES
Assess cost effective care of various skin diseases and conditions including photoaging, acne, hair and nail disease, among others.
Examine evidence that drives decision making for skin disease such as psoriasis and HS.
SCHEDULE
9:00 PM
Psoriasis: Improving outcomes and cost-effective care
Joel M. Gelfand, MD, MSCE, FAAD
9:35 PM
Cost Effective Care of Acne
John S. Barbieri, MD, MBA, FAAD
10:05 PM
Cost Effective Care of Hidradenitis Suppurativa
Joslyn S Kirby, MD, FAAD
10:35 PM
Best Cost Effective Care of Nail Disease
Brian William Morrison, MD, MSc, FAAD
11:00 PM
Cost Effective Care of Hair Loss
Mariya Miteva, MD
11:30 PM
Photo-aging: Evidenced Based Cost Effective Care
Shasa Hu, MD, FAAD
SPEAKERS
John S. Barbieri, MD, MBA, FAAD
Scott Elman, MD, FAAD
Joel M. Gelfand, MD, MSCE, FAAD
Shasa Hu, MD, FAAD
Joslyn S Kirby, MD, FAAD
Mariya Miteva, MD
Brian William Morrison, MD, MSc, FAAD
HANDOUTS
SPEAKER DISCLOSURES
John S. Barbieri, MD, MBA, FAAD
Honeydew Care – Consultant (1099 relationship)(Fees); National Institutes of Health – Other(Grants/Research Funding); National Psoriasis Foundation – Other(Grants/Research Funding);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Joel M. Gelfand, MD, MSCE, FAAD
AbbVie – Consultant(Fees); Abcentra – Consultant(Fees); Amgen – Investigator(Grants/Research Funding); Artax Biopharma – Data Safety Monitoring Board(Fees); BMS – Consultant(Fees); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); CellDex – Data Safety Monitoring Board(Fees); Daavlin Company – Other(Equipment); FIDE – Consultant(Fees); GlaxoSmithKline – Consultant(Honoraria); Happify – Consultant(Fees); Healio – Other(Fees); Imagine – Data Safety Monitoring Board(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); Janssen Pharmaceuticals, Inc – Consultant(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Consultant(Fees); Mindera – Consultant(Fees); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neumentum, Inc. – Consultant(Fees); Neuroderm LTD – Other(Fees); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); UCB – Other(Fees); Veolia North America – Consultant(Fees);
Shasa Hu, MD, FAAD
Cosmetic Dermatology, Inc – Advisory Board(Fees); L'Oreal USA Inc. – Consultant(Honoraria); Swiss American – Consultant(Honoraria);
Joslyn S Kirby, MD, FAAD
AbbVie – Speaker(Honoraria); Incyte Corporation – Employee (w-2 relationship)(Salary); Novartis – Consultant(Fees); Penn State University – Other(Patent royalties or other compensation for Intellectual Property Rights); UCB – Consultant(Fees);
Mariya Miteva, MD
Eli Lilly – Investigator(Grants/Research Funding); Informa – Other(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Brian William Morrison, MD, MSc, FAAD
No financial relationships exist with ineligible companies.